Celgene Competitors and Similar CompaniesClear all
Celgene's competitors and similar companies include Sanofi, Amgen, Gilead Sciences, Regeneron Pharmaceuticals, BioNTech and Idorsia.
 Celgene Celgene is a biopharmaceutical company developing therapies for the treatment of cancer and inflammatory diseases. |  Sanofi Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics. |  Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines. |  Regeneron Pharmaceuticals Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines. |  BioNTech BioNTech is biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. |  Idorsia Idorsia, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. | |
Founding Date | Founding Date 1986 | Founding Date 2004 | Founding Date 1980 | Founding Date 1987 | Founding Date 1988 | Founding Date 2008 | Founding Date 2017 |
Type | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||
Locations | Locations HQ | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations Foster City, US HQ Buenos Aires, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more | Locations Tarrytown, US HQ Mississauga, CA München, DE Bengaluru, IN Dublin, IE Limerick, IE Tokyo, JP see more | Locations Mainz, DE HQ Halle (Saale), DE Idar Oberstein, DE Marburg, DE Neuried, DE Planegg, DE Cambridge, US see more | Locations HQ | |
Employees | Employees 8,85219% increase | Employees 95,4424% decrease | Employees 25,200 | Employees 14,4006% increase | Employees 12,2563% increase | Employees 5,100 | Employees 8007% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 140.3 b | Valuation ($) 94.3 b | Valuation ($) 89.4 b | Valuation ($) 25.7 b | Valuation ($) N/A |
Twitter followers | Twitter followers 26.8 k | Twitter followers 151.6 k | Twitter followers 123.5 k | Twitter followers 73.8 k | Twitter followers 32.5 k | Twitter followers 83.5 k | Twitter followers 2.1 k |
Number of tweets (last 30 days) | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 35 | Number of tweets (last 30 days) 91 | Number of tweets (last 30 days) 22 | Number of tweets (last 30 days) 4 | Number of tweets (last 30 days) 2 | Number of tweets (last 30 days) 12 |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 15.6 | Average likes per tweet (last 30 days) 4.8 | Average likes per tweet (last 30 days) 48.1 | Average likes per tweet (last 30 days) 4.8 | Average likes per tweet (last 30 days) 87 | Average likes per tweet (last 30 days) 3.3 |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 91.43% | Percentage of tweets with engagement (last 30 days) 97.8% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 100% |
Employee Rating | Employee Rating 4 | Employee Rating 3.9 | Employee Rating 4.1 | Employee Rating 3.8 | Employee Rating 4 | Employee Rating 3.3 | Employee Rating 3.7 |
Financial | |||||||
Revenue (est.) | Revenue (est.) $15.3b (FY, 2018) | Revenue (est.) €43b (FY, 2022) | Revenue (est.) $26.3b (FY, 2022) | Revenue (est.) $27.3b (FY, 2022) | Revenue (est.) $12.2b (FY, 2022) | Revenue (est.) €17.3b (FY, 2022) | Revenue (est.) CHF97.1m (FY, 2022) |
Cost of goods | Cost of goods $587m (FY, 2018) | Cost of goods €11.9b (FY, 2022) | Cost of goods $6.4b (FY, 2022) | Cost of goods $5.7b (FY, 2022) | Cost of goods N/A | Cost of goods €2.9b (FY, 2022) | Cost of goods CHF6.3m (FY, 2022) |
Gross profit | Gross profit $14.7b (FY, 2018) | Gross profit €34.8b (FY, 2022) | Gross profit $19.9b (FY, 2022) | Gross profit $21.6b (FY, 2022) | Gross profit N/A | Gross profit €14.5b (FY, 2022) | Gross profit CHF90.8m (FY, 2022) |
Net income | Net income $4b (FY, 2018) | Net income €8.4b (FY, 2022) | Net income $6.6b (FY, 2022) | Net income $4.6b (FY, 2022) | Net income $4.3b (FY, 2022) | Net income €9.4b (FY, 2022) | Net income (CHF827.9m) (FY, 2022) |
Operating ⚠ | |||||||
Countries | Countries N/A | Countries N/A | Countries 100 (FY, 2020) | Countries 35 (FY, 2021) | Countries N/A | Countries N/A | Countries N/A |
Patents (EU) | Patents (EU) N/A | Patents (EU) N/A | Patents (EU) 21 (FY, 2020) | Patents (EU) N/A | Patents (EU) 17 (FY, 2020) | Patents (EU) N/A | Patents (EU) N/A |
Patents (US) | Patents (US) N/A | Patents (US) N/A | Patents (US) 31 (FY, 2020) | Patents (US) N/A | Patents (US) 31 (FY, 2020) | Patents (US) 45 (Oct, 2019) | Patents (US) N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 20 (FY, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 8 (Oct, 2019) | Phase I Trials Products N/A |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 9 (FY, 2021) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 7 (FY, 2019) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 5 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 1 (Oct, 2019) | Phase II Trials Products N/A |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 12 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 1 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products 9 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A |
Products | Products N/A | Products N/A | Products N/A | Products 21 (FY, 2021) | Products 7 (FY, 2020) | Products N/A | Products N/A |
Projects in R&D Pipeline | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 91 (FY, 2019) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 12 (FY, 2019) |
Funding | |||||||
Total funding raised | Total funding raised N/A | Total funding raised $ 310m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 53.9m | Total funding raised $ 1.4b | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Sanofi
HQ
Paris, FR
Employees
95,442↓ 4% decrease
Sanofi is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
View companyAmgen
HQ
Thousand Oaks, US
Employees
25,200
Amgen (formerly known as Applied Molecular Genetics) is a biotech company discovering, developing, manufacturing, and delivering human therapeutics.
View companyGilead Sciences
HQ
Foster City, US
Employees
14,400↑ 6% increase
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.
View companyRegeneron Pharmaceuticals
HQ
Tarrytown, US
Employees
12,256↑ 3% increase
Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines.
View company